Publicaciones destacadas

  • Hepatocellular carcinoma

    Autores: Llovet JM; Kelley RK; Villanueva A; Singal AG; Pikarsky E; Roayaie S; Lencioni R; Koike K; Zucman-Rossi J; Finn RS.
    Referencia: Nature Reviews Disease Primers 2021; 7(1):6-.
  • NASH limits anti-tumour surveillance in immunotherapy-treated HCC

    Autores: Pfister, Dominik; Nunez, Nicolas Gonzalo; Pinyol, Roser; Govaere, Olivier; Pinter, Matthias; Szydlowska, Marta; Gupta, Revant; Qiu, Mengjie; Deczkowska, Aleksandra; Weiner, Assaf; Mueller, Florian; Sinha, Ankit; Friebel, Ekaterina; Engleitner, Thomas; Lenggenhager, Daniela; Moncsek, Anja; Heide, Danijela; Stirm, Kristin; Kosla, Jan; Kotsiliti, Eleni; Leone, Valentina; Dudek, Michael; Yousuf, Suhail; Inverso, Donato; Singh, Indrabahadur; Teijeiro, Ana; Castet, Florian; Montironi, Carla; Haber, Philipp K.; Tiniakos, Dina; Bedossa, Pierre; Cockell, Simon; Younes, Ramy; Vacca, Michele; Marra, Fabio; Schattenberg, Jorn M.; Allison, Michael; Bugianesi, Elisabetta; Ratziu, Vlad; Pressiani, Tiziana; D'Alessio, Antonio; Personeni, Nicola; Rimassa, Lorenza; Daly, Ann K.; Scheiner, Bernhard; Pomej, Katharina; Kirstein, Martha M.; Vogel, Arndt; Peck-Radosavljevic, Markus; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Trojan, Jorg; Schulze, Kornelius; Wege, Henning; Koch, Sandra; Weinmann, Arndt; Bueter, Marco; Rossler, Fabian; Siebenhuner, Alexander; De Dosso, Sara; Mallm, Jan-Philipp; Umansky, Viktor; Jugold, Manfred; Luedde, Tom; Schietinger, Andrea; Schirmacher, Peter; Emu, Brinda; Augustin, Hellmut G.; Billeter, Adrian; Mueller-Stich, Beat; Kikuchi, Hiroto; Duda, Dan G.; Kutting, Fabian; Waldschmidt, Dirk-Thomas; Ebert, Matthias Philip; Rahbari, Nuh; Mei, Henrik E.; Schulz, Axel Ronald; Ringelhan, Marc; Malek, Nisar; Spahn, Stephan; Bitzer, Michael; Ruiz de Galarreta, Marina; Lujambio, Amaia; Dufour, Jean-Francois; Marron, Thomas U.; Kaseb, Ahmed; Kudo, Masatoshi; Huang, Yi-Hsiang; Djouder, Nabil; Wolter, Katharina; Zender, Lars; Marche, Parice N.; Decaens, Thomas; Pinato, David J.; Rad, Roland; Mertens, Joachim C.; Weber, Achim; Unger, Kristian; Meissner, Felix; Roth, Susanne; Jilkova, Zuzana Macek; Claassen, Manfred; Anstee, Quentin M.; Amit, Ido; Knolle, Percy; Becher, Burkhard; Llovet, Josep M.; Heikenwalder, Mathias;.
    Referencia: Nature 2021; 592(7854):450-456.
  • Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

    Autores: Llovet Bayer, Josep M.; De Baere, Thierry; KULIK, LAURA; Haber, Philipp K; Greten, Tim F; Meyer, Tim; Lencioni, Riccardo.
    Referencia: Nature Reviews Gastroenterology &Amp; Hepatology 2021; 10():1038-.
  • Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

    Autores: Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM.
    Referencia: Journal Of Clinical Oncology 2020; 38(26):2960-2970.
  • Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Autores: Zhu, Andrew X; Kang, Yoon-Koo; Yen, Chia-Jui; Finn, Richard S; Galle, Peter R; Llovet, Josep M; Assenat, Eric; Brandi, Giovanni; Pracht, Marc; Lim, Ho Yeong; Rau, Kun-Ming; Motomura, Kenta; Ohno, Izumi; Merle, Philippe; Daniele, Bruno; Shin, Dong Bok; Gerken, Guido; Borg, Christophe; Hiriart, Jean-Baptiste; Okusaka, Takuji; Morimoto, Manabu; Hsu, Yanzhi; Abada, Paolo B; Kudo, Masatoshi;REACH-2 Study Investigators.
    Referencia: Lancet Oncology 2019; 20(2):282-296.
  • Molecular therapies and precision medicine for hepatocellular carcinoma

    Autores: Llovet J; Montal R; Sia D; Finn R.
    Referencia: Nature Reviews Clinical Oncology 2018; 15(10):599-616.
  • Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

    Autores: Sia D, Jiao Y, Martinez-Quetglas I, Kuchuk O, Villacorta-Martin C, Castro de Moura M, Putra J, Camprecios G, Bassaganyas L, Akers N, Losic B, Waxman S, Thung SN, Mazzaferro V, Esteller M, Friedman SL, Schwartz M, Villanueva A, Llovet JM.
    Referencia: Gastroenterology 2017; 153(3):812-826.
  • Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma

    Autores: Sia, Daniela; Losic, Bojan; Moeini, Agrin; Cabellos, Laia; Hao, Ke; Revill, Kate; Bonal, Dennis; Miltiadous, Oriana; Zhang, Zhongyang; Hoshida, Yujin; Cornella, Helena; Castillo-Martin, Mireia; Pinyol, Roser; Kasai, Yumi; Roayaie, Sasan; Thung, Swan N; Fuster, Josep; Schwartz, Myron E; Waxman, Samuel; Cordon-Cardo, Carlos; Schadt, Eric; Mazzaferro, Vincenzo; Llovet, Josep M.
    Referencia: Nature Communications 2015; 6( ):6087-.
  • Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma

    Autores: Hoshida, Yujin; Villanueva, Augusto; Kobayashi, Masahiro; Peix, Judit; Chiang, Derek Y; Camargo, Amy; Gupta, Supriya; Moore, Jamie; Wrobel, Matthew J; Lerner, Jim; Reich, Michael; Chan, Jennifer A; Glickman, Jonathan N; Ikeda, Kenji; Hashimoto, Masaji; Watanabe, Goro; Daidone, Maria G; Roayaie, Sasan; Schwartz, Myron; Thung, Swan; Salvesen, Helga B; Gabriel, Stacey; Mazzaferro, Vincenzo; Bruix, Jordi; Friedman, Scott L; Kumada, Hiromitsu; Llovet, Josep M; Golub, Todd R.
    Referencia: New England Journal Of Medicine 2008; 359(19):1995-2004.
  • Sorafenib in advanced hepatocellular carcinoma.

    Autores: Llovet Bayer, Josep M..
    Referencia: The New England Journal Of Medicine 2008; 359(4):378-390.